Vica-Cet Back Pain Relief tablets recalled for stability specification failure
Ultra Seal Corporation is recalling Vica-Cet Back Pain Relief tablets nationwide because certain lots failed stability testing and contain out-of-specification levels of Salicylic Acid, an aspirin-related compound.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this as Class III. The recall is based on failed stability specifications with no reported illnesses, injuries, or harm. The hazard is documented but theoretical, supporting a Low severity classification.
Plain-English summary
Ultra Seal Corporation is recalling Vica-Cet Back Pain Relief tablets (Acetaminophen 250 mg / Aspirin 250 mg / Caffeine 65 mg) nationwide in the USA. The affected product consists of approximately 1,367,525 tablets packaged in 2-tablet packets as part of PO# 8967 for Tellus / The Provision First Aid Line.
The recall was initiated because stability testing revealed out-of-specification results for Salicylic Acid, an aspirin-related compound, in certain lots. The affected lots include: Lot #AK-9455 (expiration 22-Jan), Lot #AK-1109 (expiration 23-Mar), Lot #AK-1110 (expiration 23-Mar), and Lot #K-9821 (expiration 22-Sep).
Consumers who have purchased this product should stop using it. Consumers with questions or concerns should contact Ultra Seal Corporation or consult their healthcare provider.
The recalled product
- Product
- Vica-Cet BACK PAIN RELIEF (Acetaminophen 250 mg/Aspirin 250 mg/Caffeine 65 mg) tablets, 2 tablets/pk, packaged in 10,000 packets, PO# 8967, Mfg. for Tellus/The Provision First Aid Line (Shipping Label)
- Manufacturer
- Ultra Seal Corporation
- Category
- Drug — Pain Relief Tablets
- Affected units
- 1,367,525
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (7)
- Lot #: AK-9455
- exp. date 22-Jan
- AK-1109
- AK-1110
- exp. date 23-Mar
- K-9821
- exp. date 22-Sep
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 8 recalled by Ultra Seal Corporation under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 8 products in this recall →Related recalls
Same manufacturer · Ultra Seal Corporation
See all →- ModeratePEPTIME Energy Caffeine Tablets Recalled for cGMP Deviations
FDA (Drugs) · 2022-02-09
- ModerateExaprin Pain Reliever Tablets Recalled for cGMP Deviations
FDA (Drugs) · 2022-02-09
- ModerateCold Terminator decongestant recalled for cGMP deviations
FDA (Drugs) · 2022-02-09
- ModerateLite Remfresh Melatonin Tablets Recalled for cGMP Deviations
FDA (Drugs) · 2022-02-09
- ModerateExtra Strength Un-Aspirin Acetaminophen Packets Recalled for cGMP Deviations
FDA (Drugs) · 2022-02-09
Same hazard · stability failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateVasocaine lidocaine spray recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateZone 1 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateZone 2 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateCisatracurium 20 mg multiple-dose vials recalled after subpotent assay results
FDA (Drugs) · 2025-12-24